{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:57:53Z","timestamp":1787497073776,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702661"],"award-info":[{"award-number":["81702661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04458-4","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T14:04:33Z","timestamp":1667916273000},"page":"5127-5138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma"],"prefix":"10.1007","volume":"149","author":[{"given":"Jizhuang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuochao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyuan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"1","key":"4458_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.can-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, Trad M, Nt H, Cb L, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N (2014) Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Can Res 74(1):104\u2013118. https:\/\/doi.org\/10.1158\/0008-5472.can-13-1545","journal-title":"Can Res"},{"key":"4458_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdp154","volume":"20","author":"S Bielack","year":"2009","unstructured":"Bielack S, Carrle D, Casali PG, Working GEG (2009) Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:137\u2013139. https:\/\/doi.org\/10.1093\/annonc\/mdp154","journal-title":"Ann Oncol"},{"issue":"6","key":"4458_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.6004\/jnccn.2013.0088","volume":"11","author":"JS Biermann","year":"2013","unstructured":"Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, Mcgarry SV, Mcgrath B, Morris CD, O\u2019donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Von Mehren M, Bergman MA, Sundar H (2013) Bone cancer clinical practice guidelines in oncology. J Natl Comphr Cancer Netw 11(6):688\u2013723","journal-title":"J Natl Comphr Cancer Netw"},{"issue":"1","key":"4458_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"317","key":"4458_CR5","doi-asserted-by":"publisher","first-page":"317ra197","DOI":"10.1126\/scitranslmed.aad0295","volume":"7","author":"Y Chen","year":"2015","unstructured":"Chen Y, Ma DG, Molyneux S, Mckee T, Waterhouse P, Jm P, Khokha R (2015) RANKL blockade prevents and treats aggressive osteosarcomas. Sci Transl Med 7(317):317ra197. https:\/\/doi.org\/10.1126\/scitranslmed.aad0295","journal-title":"Sci Transl Med"},{"issue":"7","key":"4458_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1586\/14737140.6.7.1075","volume":"6","author":"AJ Chou","year":"2006","unstructured":"Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6(7):1075\u20131085. https:\/\/doi.org\/10.1586\/14737140.6.7.1075","journal-title":"Expert Rev Anticancer Ther"},{"key":"4458_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jbo.2017.07.001","volume":"8","author":"J Coventon","year":"2017","unstructured":"Coventon J (2017) A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. J Bone Oncol 8:4\u20137. https:\/\/doi.org\/10.1016\/j.jbo.2017.07.001","journal-title":"J Bone Oncol"},{"issue":"13","key":"4458_CR8","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1158\/0008-5472.can-13-3596","volume":"74","author":"LuX Ding Zc","year":"2014","unstructured":"Ding Zc LuX, Yu M, Lemos H, Huang L, Chandler P, Liu K, Walters M, Krasinski A, Mack M, Br B, Al M, Munn Dh, Zhou G (2014) Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Can Res 74(13):3441\u20133453. https:\/\/doi.org\/10.1158\/0008-5472.can-13-3596","journal-title":"Can Res"},{"issue":"13","key":"4458_CR9","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"Vh Francisco Lm Salinas","year":"2009","unstructured":"Francisco Lm Salinas Vh, Ke B, Vk V, Gj F, Vk K, Sharpe Ah (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015\u20133029","journal-title":"J Exp Med"},{"issue":"4","key":"4458_CR10","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/bcr2605","volume":"12","author":"H Ghebeh","year":"2010","unstructured":"Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A, Al-Tweigeri T, Aboussekhra A, Dermime S (2010) Doxorubicin downregulates cell surface B7\u2013H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7\u2013H1 as an anti-apoptotic molecule. Breast Cancer Res 12(4):R48. https:\/\/doi.org\/10.1186\/bcr2605","journal-title":"Breast Cancer Res"},{"issue":"2","key":"4458_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani G, Palmerini E, Dileo P, Asaftei SD, D\u2019ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23(2):508\u2013516. https:\/\/doi.org\/10.1093\/annonc\/mdr151","journal-title":"Ann Oncol"},{"issue":"10","key":"4458_CR12","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/eji.201242505","volume":"43","author":"L Hannesd\u00f3ttir","year":"2013","unstructured":"Hannesd\u00f3ttir L, Tymoszuk P, Parajuli N, Wasmer Mh, Philipp S, Daschil N, Datta S, Jb K, Tripp Ch, Stoitzner P, M\u00fcller-Holzner E, Gj W, Sexl V, Villunger A, Doppler W (2013) Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 43(10):2718\u20132729. https:\/\/doi.org\/10.1002\/eji.201242505","journal-title":"Eur J Immunol"},{"issue":"7","key":"4458_CR13","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/cas.13256","volume":"108","author":"C Hu","year":"2017","unstructured":"Hu C, Chen X, Wen J, Gong L, Liu Z, Wang J, Liang J, Hu F, Zhou Q, Wei L, Shen Y, Zhang W (2017) Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci 108(7):1347\u20131356. https:\/\/doi.org\/10.1111\/cas.13256","journal-title":"Cancer Sci"},{"key":"4458_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-04843-7_1","volume":"804","author":"N Jaffe","year":"2014","unstructured":"Jaffe N (2014) Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Curr Adv Osteosarcoma 804:1\u201330. https:\/\/doi.org\/10.1007\/978-3-319-04843-7_1","journal-title":"Curr Adv Osteosarcoma"},{"issue":"10043","key":"4458_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388(10043):518\u2013529","journal-title":"Lancet"},{"issue":"8","key":"4458_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1586\/era.10.79","volume":"10","author":"DG Jeon","year":"2010","unstructured":"Jeon DG, Song WS (2010) How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther 10(8):1313\u20131325. https:\/\/doi.org\/10.1586\/era.10.79","journal-title":"Expert Rev Anticancer Ther"},{"key":"4458_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130116","author":"SG Kalathil","year":"2019","unstructured":"Kalathil SG, Hutson HA, Barbi J, Iyer R, Thanavala Y (2019) Augmentation of IFN-\u03b3+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.130116","journal-title":"JCI Insight"},{"issue":"2","key":"4458_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res 76(2):227\u2013238. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3362","journal-title":"Cancer Res"},{"issue":"2","key":"4458_CR19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3892\/or.2017.5722","volume":"38","author":"J Liu","year":"2017","unstructured":"Liu J, Liu Y, Meng L, Liu K, Ji B (2017) Targeting the PD-L1\/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 38(2):899\u2013907. https:\/\/doi.org\/10.3892\/or.2017.5722","journal-title":"Oncol Rep"},{"issue":"3","key":"4458_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41419-022-04744-6","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Leng A, Li L, Yang B, Shen S, Chen H, Zhu E, Xu Q, Ma X, Shi P, Liu Y, Liu T, Li L, Li K, Zhang D, Xiao J (2022) AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGF\u03b2 signaling pathway. Cell Death Dis 13(3):288. https:\/\/doi.org\/10.1038\/s41419-022-04744-6","journal-title":"Cell Death Dis"},{"issue":"4","key":"4458_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ctrv.2013.11.006","volume":"40","author":"A Luetke","year":"2014","unstructured":"Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment\u2014where do we stand? A state of the art review. Cancer Treat Rev 40(4):523\u2013532. https:\/\/doi.org\/10.1016\/j.ctrv.2013.11.006","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"4458_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/15384047.2017.1294285","volume":"18","author":"Q Ma","year":"2017","unstructured":"Ma Q, Zhang Y, Liu T, Jiang K, Wen Y, Fan Q, Qiu X (2017) Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma. Cancer Biol Ther 18(3):177\u2013185. https:\/\/doi.org\/10.1080\/15384047.2017.1294285","journal-title":"Cancer Biol Ther"},{"issue":"7203","key":"4458_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436\u2013444. https:\/\/doi.org\/10.1038\/nature07205","journal-title":"Nature"},{"issue":"12","key":"4458_CR24","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1093\/annonc\/mdx536","volume":"28","author":"J Martin-Broto","year":"2017","unstructured":"Martin-Broto J, Redondo A, Valverde C, Ma V, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Ds M, Luna P, Hindi N, Lopez-Pousa A (2017) Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Ann Oncol 28(12):2994\u20132999. https:\/\/doi.org\/10.1093\/annonc\/mdx536","journal-title":"Ann Oncol"},{"issue":"22","key":"4458_CR25","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer PS, Helman LJ (2021) New horizons in the treatment of osteosarcoma. N Engl J Med 385(22):2066\u20132076. https:\/\/doi.org\/10.1056\/NEJMra2103423","journal-title":"N Engl J Med"},{"issue":"7","key":"4458_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1158\/2326-6066.CIR-15-0252","volume":"4","author":"EC Moore","year":"2016","unstructured":"Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT (2016) Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol Res 4(7):611\u2013620. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0252","journal-title":"Cancer Immunol Res"},{"key":"4458_CR27","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3389\/fimmu.2017.01476","volume":"8","author":"E Muraro","year":"2017","unstructured":"Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo M (2017) Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer. Front Immunol 8:1476. https:\/\/doi.org\/10.3389\/fimmu.2017.01476","journal-title":"Front Immunol"},{"issue":"67","key":"4458_CR28","doi-asserted-by":"publisher","first-page":"111836","DOI":"10.18632\/oncotarget.22912","volume":"8","author":"E Palmerini","year":"2017","unstructured":"Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S (2017) Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8\/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget 8(67):111836\u2013111846. https:\/\/doi.org\/10.18632\/oncotarget.22912","journal-title":"Oncotarget"},{"issue":"1","key":"4458_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","volume":"13","author":"JA Park","year":"2020","unstructured":"Park JA, Cheung NV (2020) GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol 13(1):172. https:\/\/doi.org\/10.1186\/s13045-020-01012-y","journal-title":"J Hematol Oncol"},{"issue":"23","key":"4458_CR30","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.can-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Sk M, Konishi I, Mandai M (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Can Res 75(23):5034\u20135045. https:\/\/doi.org\/10.1158\/0008-5472.can-14-3098","journal-title":"Can Res"},{"key":"4458_CR31","first-page":"OL1366","volume":"56","author":"X Qin","year":"2010","unstructured":"Qin X, Liu C, Zhou Y, Wang G (2010) Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk \/MAPK signaling pathway. Cell Mol Biol 56:OL1366-1372","journal-title":"Cell Mol Biol"},{"issue":"1","key":"4458_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-016-1925-3","volume":"66","author":"YT Sundara","year":"2017","unstructured":"Sundara YT, Kostine M, Cleven AH, Bovee JV, Schilham MW, Cleton-Jansen AM (2017) Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother 66(1):119\u2013128. https:\/\/doi.org\/10.1007\/s00262-016-1925-3","journal-title":"Cancer Immunol Immunother"},{"key":"4458_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-4509","author":"A Takemoto","year":"2022","unstructured":"Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, Kobayashi A, Lebel M, Kawaguchi T, Sugawara M, Tsuji-Takayama K, Ichihara K, Funauchi Y, Ae K, Matsumoto S, Sugiura Y, Takeuchi K, Noda T, Katayama R, Fujita N (2022) Targeting podoplanin for the treatment of osteosarcoma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-4509","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4458_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CJI.0000000000000281","volume":"42","author":"J Wang","year":"2019","unstructured":"Wang J, Hu C, Wang J, Shen Y, Bao Q, He F, Wang H, Gong L, Liu Z, Hu F, Liang J, Zhou Q, Wei L, Wen J, Zhang W (2019) Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma. J Immunother 42(9):321\u2013330. https:\/\/doi.org\/10.1097\/CJI.0000000000000281","journal-title":"J Immunother"},{"issue":"19","key":"4458_CR35","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, Mcnabola A, Rong H, Chen C, Zhang X, Vincent P, Mchugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099\u20137109. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1443","journal-title":"Cancer Res"},{"issue":"4","key":"4458_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1878-0261.12032","volume":"11","author":"M Yang","year":"2017","unstructured":"Yang M, Liu P, Wang K, Glorieux C, Hu Y, Wen S, Jiang W, Huang P (2017) Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. Mol Oncol 11(4):358\u2013372. https:\/\/doi.org\/10.1002\/1878-0261.12032","journal-title":"Mol Oncol"},{"issue":"16","key":"4458_CR38","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.3390\/ijms23169345","volume":"23","author":"YT Yang","year":"2022","unstructured":"Yang YT, Vilma YG (2022) Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines. Int J Mol Sci 23(16): 9345","journal-title":"Int J Mol Sci"},{"issue":"22","key":"4458_CR39","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1158\/0008-5472.can-10-1825","volume":"70","author":"R Zappasodi","year":"2010","unstructured":"Zappasodi R, Sm P, Gc G, Bongarzone I, Magni M, Cabras Ad, Mp C, Carlo-Stella C, Am G, Di Nicola M (2010) Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Can Res 70(22):9062\u20139072. https:\/\/doi.org\/10.1158\/0008-5472.can-10-1825","journal-title":"Can Res"},{"issue":"5","key":"4458_CR40","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.molimm.2007.08.013","volume":"45","author":"P Zhang","year":"2008","unstructured":"Zhang P, Su DM, Liang M, Fu J (2008) Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 45(5):1470\u20131476. https:\/\/doi.org\/10.1016\/j.molimm.2007.08.013","journal-title":"Mol Immunol"},{"issue":"5","key":"4458_CR41","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.nano.2016.01.017","volume":"12","author":"J Zhang","year":"2016","unstructured":"Zhang J, Hu J, Chan HF, Skibba M, Liang G, Chen M (2016) iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomedicine 12(5):1303\u20131311. https:\/\/doi.org\/10.1016\/j.nano.2016.01.017","journal-title":"Nanomedicine"},{"issue":"2","key":"4458_CR42","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.bbrc.2017.12.032","volume":"495","author":"B Zheng","year":"2018","unstructured":"Zheng B, Ren T, Huang Y, Guo W (2018) Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun 495(2):1695\u20131701. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.032","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04458-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04458-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T10:16:57Z","timestamp":1689416217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04458-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4458"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04458-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The protocol was approved by the animal ethical committee of Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}